- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02699099
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
September 7, 2021 updated by: GlaxoSmithKline
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6 months at the first vaccination.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
699
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kintampo, Ghana
- GSK Investigational Site
-
Kumasi, Ghana
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 6 years (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects' parent(s)/Legally Acceptable Representative(s) (LAR[s]) who, in the opinion of the investigator, could and complied with the requirements of the protocol.
- A male or female 6 months of age (from the day the child becomes 6 months of age until the day before the child achieved 7 months of age) at the time of the first vaccination.
- Signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the subject. Where parent(s)/LAR(s) were illiterate, the consent form was countersigned by an independent witness.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Previously received three documented doses of diphtheria, tetanus, and whole-cell pertussis, hepatitis B vaccine (DTPwHepB), and a 3-dose course of oral polio vaccine and, if locally recommended, pneumococcal and rotavirus vaccines.
Exclusion Criteria:
- Child in care
- Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this meant prednisone≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids were allowed.
- Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting seven days before the first dose of SB257049 measles, rubella and YF vaccines and ending 42 days after the last dose of vaccines given at 9 months of age (Visit 4), with the exception of oral polio vaccine which could be given for unforeseen public health threat.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- Previous vaccination against measles, YF or rubella.
- Previous administration of Vitamin A.
- Moderate or severe malnutrition at screening defined as weight for age Z-score < -2.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s). See also Section 1.3.
- Major congenital defects or serious chronic illness.
- History of any neurological disorders or seizures.
- Acute disease and/or fever at the time of enrolment. Fever was defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study was axillary.
Subjects with a minor illness without fever might have been enrolled at the discretion of the investigator.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- Same sex twin.
- Maternal death.
- Previous participation in any other malaria study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Coad group
Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age.
Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
|
Oral administration of Vitamin A (1 dose)
Intramuscular administration of SB257049 vaccine (4 doses)
Other Names:
Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
Other Names:
Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
Other Names:
|
EXPERIMENTAL: RTS,S group
Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age.
Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
|
Oral administration of Vitamin A (1 dose)
Intramuscular administration of SB257049 vaccine (4 doses)
Other Names:
Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
Other Names:
Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
Other Names:
|
EXPERIMENTAL: Control group
Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age.
These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
|
Oral administration of Vitamin A (1 dose)
Intramuscular administration of SB257049 vaccine (4 doses)
Other Names:
Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
Other Names:
Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis)
Time Frame: At one month post Dose 3 of SB257049 (Month 4)
|
Concentrations were expressed as Geometric Mean Concentrations (GMCs) with the following unit of measure: Enzyme Linked Immunosorbent Assay (ELISA) units per milliliter (EU/mL).
The 95% confidence intervals were calculated using the Analysis of Variance (ANOVA) model.
The antibody response of anti-CS was assessed in the Coad Group and the RTS,S Group.
|
At one month post Dose 3 of SB257049 (Month 4)
|
Anti-CS Antibody Concentrations, One Month Post Dose 3 of SB257049 (Study End Analysis)
Time Frame: At one month post Dose 3 of SB257049 (Month 4)
|
Concentrations were expressed as GMCs with the following unit of measure: EU/mL.
The 95% confidence intervals were calculated using the ANOVA model.
The antibody response of anti-CS was assessed in the Coad Group and the RTS,S Group.
The analysis was re-evaluated and performed on the Per-Protocol set for immunogenicity defined at study end.
|
At one month post Dose 3 of SB257049 (Month 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-CS Antibody Concentrations, Pre-vaccination and One Month Post Dose 3 of SB257049
Time Frame: At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
Concentrations were expressed as Geometric Mean Concentrations (GMCs) with the following unit of measure: ELISA units per milliliter (EU/mL).
The 95% CI for the GMC was obtained by exponential transformation (base 10) of the 95% CI for the mean of the log transformed concentrations.
The antibody response of anti-CS was assessed in the Coad Group and the RTS,S Group.
|
At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
Number of Seropositive Subjects for Anti-CS Antibodies, Pre-vaccination and One Month Post Dose 3 of SB257049
Time Frame: At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
A subject seropositive for anti-CS antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-CS ≥ 1.9 ELISA unit per milliliter [EU/mL]).
Seropositivity was assessed in the Coad Group and the RTS,S Group.
|
At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
Anti-hepatitis B (Anti-HBs) Antibody Concentrations, Pre-vaccination and One Month Post-Dose 3 of SB257049
Time Frame: At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
Concentrations were expressed as GMCs with the following unit of measure: milli-international unit per milliliter (mIU/mL).
The antibody response of anti-HB was assessed in the Coad Group and the RTS,S Group.
|
At Day 0 and one month post Dose 3 of SB257049 (Month 4)
|
Number of Seroprotected Subjects for Anti-HB Antibodies, Pre-vaccination and One Month Post-Dose 3 of SB257049
Time Frame: At Day 0 and one month post-Dose 3 of SB257049 (Month 4)
|
Seroprotection rate for anti-HBs antibody was defined as the percentage of subjects with antibody concentrations greater than or equal to an established cut-off value (anti-HBs ≥ 10 milli-international unit per milliliter [mIU/mL]).
Seroprotection was assessed in the Coad Group and the RTS,S Group.
|
At Day 0 and one month post-Dose 3 of SB257049 (Month 4)
|
Number of Seroconverted Subjects for Anti-Measles (Anti-Me) Antibodies, One Month Post-vaccination With the Combined Measles and Rubella (MeRu) Vaccine
Time Frame: At one month post-vaccination with the combined measles and rubella (MeRu) vaccine (Month 4)
|
Seroconversion was defined as number of subjects with an anti-Measles antibodies pre-vaccination concentration below 150 mIU/mL and a post-vaccination concentration ≥150 mIU/mL.
Seroconversion was assessed in the Coad group and the Control group.
|
At one month post-vaccination with the combined measles and rubella (MeRu) vaccine (Month 4)
|
Anti-Me Antibody Concentrations, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine
Time Frame: At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Concentrations were expressed in GMCs with the following unit of measure: milli-international unit per milliliter (mIU/mL).
The antibody response of anti-Me was assessed in the Coad Group and the Control Group.
|
At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Number of Seropositive Subjects for Anti-Me Antibodies, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine
Time Frame: At pre-vaccination (Month 3) and one month post-vaccination with the combined measles and rubella vaccine (Month 4)
|
A subject seropositive for anti-CS antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-Me ≥ 150 mIU/mL).
Seropositivity was assessed in the Coad Group and the Control Group.
|
At pre-vaccination (Month 3) and one month post-vaccination with the combined measles and rubella vaccine (Month 4)
|
Number of Seroconverted Subjects for Anti-Rubella (Anti-Ru) Antibodies, One Month Post-vaccination With the Combined Measles and Rubella Vaccine
Time Frame: At one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Seroconversion was defined as number of subjects with an anti-Ru pre-vaccination concentration less than (<) 4 IU/mL and a post-vaccination concentration ≥ 4 IU/mL.
Seroconversion was assessed in the Coad group and Control group.
|
At one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Anti-Ru Antibody Concentrations, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine
Time Frame: At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Concentrations were expressed as GMCs with the following unit of measure: International unit per milliliter (IU/mL).
The antibody response of anti-Ru was assessed in the Coad Group and Control Group.
|
At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Number of Seropositive Subjects for Anti-Ru Antibodies, Pre-vaccination and One Month Post-vaccination With the Combined Measles and Rubella Vaccine
Time Frame: At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
A subject seropositive for anti-Ru antibody was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value (anti-Ru ≥ 4 IU/mL).
Seropositivity was assessed in the Coad Group and Control Group.
|
At pre-vaccination (Month 3) and one month post-vaccination with combined measles and rubella vaccine (Month 4)
|
Number of Seropositive Subjects for Anti-Yellow Fever (Anti-YF) Antibodies, at One Month Post-vaccination With the YF Vaccine
Time Frame: At one month post-vaccination with the YF vaccine (Month 4)
|
Seropositivity was defined as number of subjects with anti-YF titers greater than or equal to (≥) 10 End point Dilution 50 (ED50).
Seropositivity was assessed in the Coad group and Control group.
|
At one month post-vaccination with the YF vaccine (Month 4)
|
Anti-YF Antibody Titers One Month Post-vaccination With the YF Vaccine
Time Frame: At one month post-vaccination with the YF vaccine (Month 4)
|
Titers were expressed as Geometric Mean Titres (GMTs).
The antibody response of anti-YF was assessed in the Coad Group and Control Group.
|
At one month post-vaccination with the YF vaccine (Month 4)
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms for Coad Group and RTS,S Group After Administration of Vitamin A and Study Vaccines at 6 Months of Age
Time Frame: During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = subject crying when limb was moved /spontaneously painful.
Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) at injection site.
|
During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)
|
Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Coad Group and RTS,S Group After Administration of Vitamin A and Study Vaccines at 6 Months of Age
Time Frame: During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)
|
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite, measles/rubella-like rash and fever.
Any = occurrence of the symptom regardless of intensity grade.
Any Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).
Grade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability/Fussiness = Crying that couldn't be comforted/prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles /rubella rash = >150 lesions; Grade 3 fever= temperature grater than (>) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination.
|
During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A and SB257049 dose 1 (Day 0)
|
Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Control Group After Administration of Vitamin A at 6 Months of Age
Time Frame: During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A (Day 0)
|
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite, measles/rubella-like rash and fever.
Any = occurrence of the symptom regardless of intensity grade.
Any Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).
Grade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability/Fussiness = Crying that couldn't be comforted/prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles /rubella rash = >150 lesions; Grade 3 fever= temperature grater than (>) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination.
|
During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of Vitamin A (Day 0)
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms for Coad Group and RTS,S Group After Dose of Study Vaccines Administered at 7.5 Months of Age
Time Frame: During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = subject crying when limb was moved /spontaneously painful.
Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimetres (mm) at injection site.
|
During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)
|
Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for the Coad Group and RTS,S Group After Dose of Study Vaccines Administered at 7.5 Months of Age
Time Frame: During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)
|
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite, measles/rubella-like rash and fever.
Any = occurrence of the symptom regardless of intensity grade.
Any Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).
Grade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability/Fussiness = Crying that couldn't be comforted/prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles /rubella rash = >150 lesions; Grade 3 Fever= temperature grater than (>) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination.
|
During a 7-day follow-up period (day of administration and 6 subsequent days) after administration of SB257049 dose 2 (Month 1.5)
|
Number of Subjects With Solicited General Symptoms for the Control Group, After Visit at 7.5 Months of Age
Time Frame: After visit at Month 1.5
|
Solicited symptoms were not analyzed for the Control Group after visit at Month 1.5 because no vaccination was administered at that visit.
|
After visit at Month 1.5
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms for All Groups, After Dose of Study Vaccines Administered at 9 Months of Age
Time Frame: During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = subject crying when limb was moved /spontaneously painful.
Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) at injection site.
|
During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)
|
Number of Subjects With Any, Grade 3, Related, Grade 3 and Related Solicited General Symptoms for All Groups, After Dose of Study Vaccines Administered at 9 Months of Age
Time Frame: During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)
|
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite, measles/rubella-like rash and fever.
Any = occurrence of the symptom regardless of intensity grade.
Any Fever = temperature greater than or equal to (≥) 37.5° C (axillary route).
Grade 3 drowsiness= symptom that prevented normal activity; Grade 3 Irritability/Fussiness = Crying that couldn't be comforted/prevented normal activity; Grade 3 Loss of appetite = not eating at all; Grade 3 Measles /rubella rash = >150 lesions; Grade 3 Fever= temperature grater than (>) 39°C; Related = symptom assessed by the investigator as causally related to the vaccination.
|
During a 14-day follow-up period (day of administration and 13 subsequent days) after administration of SB257049 dose 3 in Coad (and MeRu+YF) and RTS,S Groups and after MeRu+YF vaccines in Control Group (Month 3)
|
Number of Subjects With Unsolicited Adverse Events (AEs) for All Groups, After Administration of Vitamin A and Study Vaccines at 6 Months of Age
Time Frame: Within 30-day (Days 0-29) period after dose 1 of SB257049 and Vitamin A- Coad and RTS,S Groups, and 30-day period after Vitamin A administration - Control Group
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 30-day (Days 0-29) period after dose 1 of SB257049 and Vitamin A- Coad and RTS,S Groups, and 30-day period after Vitamin A administration - Control Group
|
Number of Subjects With Unsolicited AEs for the Coad Group and RTS,S Group, After Dose of Study Vaccines at 7.5 Months of Age
Time Frame: Within 30-day (Day of vaccination and 29 subsequent days) period after dose 2 of SB257049 administered at Month 1.5 - Coad and RTS,S Groups
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 30-day (Day of vaccination and 29 subsequent days) period after dose 2 of SB257049 administered at Month 1.5 - Coad and RTS,S Groups
|
Number of Subjects With Unsolicited AEs for the Control Group, at Visit at 7.5 Months of Age
Time Frame: During the 30-day period (Day of the visit and 29 subsequent days) after the visit at Month 1.5
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
During the 30-day period (Day of the visit and 29 subsequent days) after the visit at Month 1.5
|
Number of Subjects With Unsolicited AEs for All Study Groups, After Dose of Study Vaccines Administered at 9 Months of Age
Time Frame: Within 42-day (vaccination day and 41 subsequent days) period after dose 3 of SB257049 in Coad (+MeRu+YF vaccines) and RTS,S groups, and 42-day period after MeRU+YF vaccination in Control group, administered at Month 3
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 42-day (vaccination day and 41 subsequent days) period after dose 3 of SB257049 in Coad (+MeRu+YF vaccines) and RTS,S groups, and 42-day period after MeRU+YF vaccination in Control group, administered at Month 3
|
Number of Subjects With Serious Adverse Events (SAEs): All, Fatal and Related, for All Study Groups, Following Each Administration at Day 0, Month1.5 and Month 3
Time Frame: During 30-Days period (Day of vaccination and 29 subsequent days) following each administration at Day 0, Month1.5 and Month 3 for Coad and RTS,S groups and at Day 0 and Month 3 in the Control Group.
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During 30-Days period (Day of vaccination and 29 subsequent days) following each administration at Day 0, Month1.5 and Month 3 for Coad and RTS,S groups and at Day 0 and Month 3 in the Control Group.
|
Number of Subjects With Any SAEs for All Study Groups, From Day 0 Until Month 4.5
Time Frame: From Day 0 up to Month 4.5
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From Day 0 up to Month 4.5
|
Number of Subjects With Potential Immune-Mediated Disease (pIMDs) for All Study Groups From Day 0 Until Month 4.5
Time Frame: From Day 0 up to Month 4.5
|
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune etiology.
|
From Day 0 up to Month 4.5
|
Number of Subjects With Meningitis for All Study Groups From Day 0 Until Month 4.5
Time Frame: From Day 0 up to Month 4.5
|
Meningitis is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It was assessed by the investigator as specific to the treatment administration.
|
From Day 0 up to Month 4.5
|
Number of Subjects With Seizures for All Groups, Post-vaccination for Vaccines Administered at 6, 7.5 or 9 Months of Age
Time Frame: Within 30 days post-vaccination for vaccine doses administered at Day 0, Month 1.5 or 42 days post-vaccination (doses given at Month 3 [Coad & Control Groups] or Month 4.5 [RTS,S Group]) vaccination period from Day 0 until Month 4.5
|
Seizure is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It is assessed by the investigator as specific to the treatment administration.
|
Within 30 days post-vaccination for vaccine doses administered at Day 0, Month 1.5 or 42 days post-vaccination (doses given at Month 3 [Coad & Control Groups] or Month 4.5 [RTS,S Group]) vaccination period from Day 0 until Month 4.5
|
Number of Subjects With Generalized Convulsive Seizure for All Study Groups, After Vaccines Administered at Day 0 and Month 1.5 (Coad and RTS,S Groups) and After Vaccines Administered at Month 3 (All Groups)
Time Frame: Within 7 days after vaccines administered at Day 0 and Month 1.5 for the Coad and RTS,S groups and 14 days after vaccines administered at Month 3 for all groups
|
Generalized convulsive seizure is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It is assessed by the investigator as specific to the treatment administration.
|
Within 7 days after vaccines administered at Day 0 and Month 1.5 for the Coad and RTS,S groups and 14 days after vaccines administered at Month 3 for all groups
|
Number of Subjects With Unsolicited AEs for the Coad Group and RTS,S Group, After the Booster Dose of Study Vaccine Administered at 27 Months of Age
Time Frame: During the 30-day period (Day of vaccination and 29 subsequent days) after booster dose administered at Month 21
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
During the 30-day period (Day of vaccination and 29 subsequent days) after booster dose administered at Month 21
|
Number of Subjects With Unsolicited AEs for the Control Group, After Dose of Study Vaccine Administered at 10.5, 11.5, 12.5 and 30 Months of Age
Time Frame: During the 30-Day Period (Day of vaccination and 29 subsequent days) after primary doses of study vaccine administered at Month 4.5, Month 5.5, Month 6.5 (across primary doses), and after booster dose administered at Month 24
|
An unsolicited adverse event is any adverse event (i.e.
any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
During the 30-Day Period (Day of vaccination and 29 subsequent days) after primary doses of study vaccine administered at Month 4.5, Month 5.5, Month 6.5 (across primary doses), and after booster dose administered at Month 24
|
Number of Subjects With SAEs for All Study Groups From Day 0 Until Study End
Time Frame: During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
Number of Subjects With pIMDs for All Study Groups From Day 0 Until Study End
Time Frame: During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune etiology.
|
During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
Number of Subjects With Meningitis for All Study Groups From Day 0 Until Study End
Time Frame: During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
Meningitis is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It is assessed by the investigator as specific to the treatment administration.
|
During the entire study period (From Day 0 until Month 33 for Coad and RTS,S Groups and Month 36 for the Control Group)
|
Number of Subjects With Seizures for Vaccines Doses Administered at 6, 7.5, 27 Months of Age for Coad and RTS,S Groups; and at 9 Months of Age for Coad Group or 10.5 Months of Age for RTS,S Group
Time Frame: Within 30 days post-vaccination (doses given at Day 0, Month 1.5, Month 21) & 42 days post-vaccination (dose given at Month 3 [Coad Group] or Month 4.5 [RTS,S Group])
|
Seizure is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It was assessed by the investigator as specific to the treatment administration.
Results are presented across all doses for Coad and RTS,S Groups.
|
Within 30 days post-vaccination (doses given at Day 0, Month 1.5, Month 21) & 42 days post-vaccination (dose given at Month 3 [Coad Group] or Month 4.5 [RTS,S Group])
|
Number of Subjects With Seizures for Vaccines Doses Administered at 10.5, 11.5, 12.5, 30 and 9 Months of Age for Control Group
Time Frame: Within 30 days post-vaccination (doses given at Month 4.5, Month 5.5, Month 6.5, Month 24) & 42 days post-vaccination (dose given at Month 3)
|
Seizure is an adverse event of specific interest (AESI).
An AESI is defined as an AE including autoimmune diseases and other mediated inflammatory disorders.
It was assessed by the investigator as specific to the treatment administration.
Results are presented across all doses for the Control Group.
|
Within 30 days post-vaccination (doses given at Month 4.5, Month 5.5, Month 6.5, Month 24) & 42 days post-vaccination (dose given at Month 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 10, 2017
Primary Completion (ACTUAL)
March 14, 2018
Study Completion (ACTUAL)
October 7, 2020
Study Registration Dates
First Submitted
February 23, 2016
First Submitted That Met QC Criteria
February 29, 2016
First Posted (ESTIMATE)
March 4, 2016
Study Record Updates
Last Update Posted (ACTUAL)
September 29, 2021
Last Update Submitted That Met QC Criteria
September 7, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Parasitic Diseases
- Protozoan Infections
- Hemorrhagic Fevers, Viral
- Togaviridae Infections
- Rubivirus Infections
- Malaria
- Yellow Fever
- Rubella
- Physiological Effects of Drugs
- Immunologic Factors
- Micronutrients
- Vitamins
- Vaccines
- Vitamin A
Other Study ID Numbers
- 200596
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Vitamin A
-
Ohio State University Comprehensive Cancer CenterRecruitingAllogeneic Hematopoietic Stem Cell Transplantation RecipientUnited States
-
Institut de Recherche pour le DeveloppementUniversity of Copenhagen; Thrasher Research Fund; National Institute of Nutrition...CompletedMaking Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and InflammationHealthy Women Giving Birth to Singleton InfantsVietnam
-
Sheba Medical CenterNot yet recruitingThe Relationship Between Oral Vitamin A Administration and the Incidence of BPD in Preterm Infants Born Before Week 29 of Pregnancy
-
University GhentFlemish Interuniversity Council (VLIR); Arba Minch University, EthiopiaCompletedVitamin A Deficiency | Anemia, Iron Deficiency | Cognitive Development | Helminthic InfectionEthiopia
-
Tehran University of Medical SciencesUnknownAtherosclerosisIran, Islamic Republic of
-
Instituto Materno Infantil Prof. Fernando FigueiraCompletedVitamin A Deficiency | HypovitaminosisBrazil
-
Eunice Kennedy Shriver National Institute of Child...Unknown
-
Shiraz University of Medical SciencesNot yet recruiting
-
National Food Technology Research Centre, BotswanaNetherlands: Ministry of Health, Welfare and Sports; UNICEF; University of BotswanaUnknownAssessment of Vitamin A Status of Children
-
Medical Research Council, South AfricaUniversity of Wisconsin, Madison; International Atomic Energy AgencyCompletedHypervitaminosis ASouth Africa